Moberg Derma: Recruitment Completed for Limtop Phase II Study in AK

Published: Sep 06, 2012

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Derma AB (STO:MOB)(OMX: MOB) has successfully completed the recruitment of 97 patients with Actinic Keratosis (AK) on the head or face for the on-going Limtop phase II study. The aim is to evaluate the efficacy and safety of three different dose regimens of Limtop. The results are expected in the first half of 2013.

Back to news